Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.02170 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Paolo Tarantino und 51 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Paclitaxel, Ado-Trastuzumab Emtansine. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)–positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet need. METHODS In the ATEMPT phase II trial, patients with stage I centrally confirmed HER2-positive breast cancer were randomly assigned 3:1 to adjuvant T-DM1 for 1 year or paclitaxel plus trastuzumab (TH). Coprimary objectives were to compare the incidence of clinically relevant toxicities between arms and to evaluate invasive disease-free survival (iDFS) with T-DM1. Correlative analyses included the HER2DX genomic tool, multiomic evaluations of HER2 heterogeneity, and predictors of thrombocytopenia. RESULTS After a median follow-up of 5.8 years, 11 iDFS events were observed in the T-DM1 arm, consistent with a 5-year iDFS of 97.0% (95% CI, 95.2 to 98.7). At 5 years, the recurrence-free interval (RFI) was 98.3% (95% CI, 97.0 to 99.7), the overall survival was 97.8% (95% CI, 96.3 to 99.3), and the breast cancer-specific survival was 99.4% (95% CI, 98.6 to 100). Comparable iDFS was observed with T-DM1 irrespective of tumor size, hormone receptor status, centrally determined HER2 immunohistochemical score, and receipt of T-DM1 for more or less than 6 months. Although ATEMPT was not powered for this end point, the 5-year iDFS in the TH arm was 91.1%. Among patients with sufficient tissue for HER2DX testing (n = 187), 5-year outcomes significantly differed according to HER2DX risk score, with better RFI (98.1% v 81.8%, hazard ratio [HR], 0.10, P = .01) and iDFS (96.3% v 81.8%, HR, 0.20, P = .047) among patients with HER2DX low-risk versus high-risk tumors, respectively. CONCLUSION Adjuvant T-DM1 for 1 year leads to outstanding long-term outcomes for patients with stage I HER2-positive breast cancer. A high HER2DX risk score predicted a higher risk of recurrence in ATEMPT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
- Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.
- Harvard Medical School, Boston, MA.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
- Division of Data Science, Dana-Farber Cancer Institute, Boston, MA.
- SOLTI Breast Cancer Research Group, Barcelona, Spain.
ORCID-Profile: Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Steven J Isakoff, Therese Mulvey, Ron Bose, Antonio C Wolff, Katherine Reeder-Hayes, Hope S Rugo, Dan Zuckerman, Vijayakrishna K Gadi, Kit Cheng, P Kelly Marcom, Kathy Albain, Nadine Tung, Rita Nanda, Rachel C Jankowitz, Mothaffar Rimawi, Vandana Abramson, Catherine Van Poznak, Andres Forero-Torres, Minetta C Liu, Kathryn J Ruddy, Harold J Burstein, Ann H Partridge, Emma Krause, Busem Binboğa Kurt, Elizabeth A Mittendorf, Bryan Schneider, Aleix Prat, Eric P Winer, Ian E Krop, Sara M Tolaney
Förderung
- NCI NIH HHS
Zitieren
APA
Tarantino, P., Tayob, N., Villacampa, G., Dang, C., Yardley, D. A., Isakoff, S. J., Valero, V., Faggen, M., Mulvey, T., Bose, R., Weckstein, D., Wolff, A. C., Reeder-Hayes, K., Rugo, H. S., Ramaswamy, B., Zuckerman, D., Hart, L., Gadi, V. K., Constantine, M., …, & TBCRC Translational Investigators (2024). Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02170
Vancouver
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, et al. Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.02170
BibTeX
@article{Tarantino2024,
author = {Tarantino, Paolo and Tayob, Nabihah and Villacampa, Guillermo and Dang, Chau and Yardley, Denise A and Isakoff, Steven J and Valero, Vicente and Faggen, Meredith and Mulvey, Therese and Bose, Ron and Weckstein, Douglas and Wolff, Antonio C and Reeder-Hayes, Katherine and Rugo, Hope S and Ramaswamy, Bhuvaneswari and Zuckerman, Dan and Hart, Lowell and Gadi, Vijayakrishna K and Constantine, Michael and Cheng, Kit and Garrett, Audrey Merrill and Marcom, P Kelly and Albain, Kathy and DeFusco, Patricia and Tung, Nadine and Ardman, Blair and Nanda, Rita and Jankowitz, Rachel C and Rimawi, Mothaffar and Abramson, Vandana and Pohlmann, Paula R and Van Poznak, Catherine and Forero-Torres, Andres and Liu, Minetta C and Ruddy, Kathryn J and Waks, Adrienne G and DeMeo, Michelle and Burstein, Harold J and Partridge, Ann H and Dell'Orto, Patrizia and Russo, Leila and Krause, Emma and Newhouse, Daniel J and Kurt, Busem Binboğa and Mittendorf, Elizabeth A and Schneider, Bryan and Prat, Aleix and Winer, Eric P and Krop, Ian E and Tolaney, Sara M and Consortium of the TBCRC Translational Investigators, Consortium of the TBCRC Translational Investigators and TBCRC Translational Investigators, TBCRC Translational Investigators},
title = {Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.02170}
}
EUVIMED